ExplainersExplainer, with music, 0:24 · 21 of 28
100 Patients
Picture 100 people who already have advanced precancer.
Applying the published 43.4% sensitivity, about 43 would test positive and about 57 would test negative in one screening round.
The evidence behind it
The full caption
A 100-person illustration, not a separate trial: all 100 already have advanced precancer. Applying the published BLUE-C sensitivity of 43.4%, about 43 would test positive and about 57 would test negative in one screening round. It does not mean 57% of all screened adults have missed disease or that 57% of negative tests conceal precancer.
Colonoscopy can find and remove detected precancerous polyps during the same exam. It can also miss lesions and has preparation, sedation, bleeding, perforation, and other burdens or risks. Stool-based screening remains a guideline-supported option; a positive stool test requires colonoscopy. Choose a screening plan you can complete with your clinician.
BLUE-C was funded by Exact Sciences, maker of Cologuard Plus; multiple published-study authors were company employees. Single-round test performance does not establish lifetime screening outcomes.